Application research on human amniotic membrane has been carried out for nearly a hundred years and people found that there were more than dozens of kinds bioactive substances in the amniotic membrane. It has been proved that the amniotic membrane has a lot of functions, such as anti-inflammatory, anti-bacterial, anti-virus, anti-angiogenic and promoting cell apoptosis, and so on. As effective treatments, amniotic membrane has been used for adjunctive therapy of burns, trauma, ophthalmic damage, dermatopathya. Recent advances of amniotic membrane and amniotic membrane-derived cells research have led to enormous progress in skin tissue engineering, vascular tissue engineering, biological scaffold material, and biological sustained-release materials. Amniotic membrane and amniotic membrane derived cells have a significant advantage and unique charm in medical field. Therefore, they have higher research value and broad prospects in the applications.
Since the release rate of protein in hydrogels is directly dependent upon the size of the protein and the hydrogel, how to deliver low molecular weight protein for prolonged periods has always been a problem. In this article, we present a usage of self-assembling peptide (P3) with the RGD epitope on its N terminus. The concentration of the released insulin-like growth factor 1 (IGF-1) was determined by UV-vis spectroscopy and the release kinetics suggested a notable reduction of the IGF-1 release rate. Cell entrapment experiments revealed that IGF-1 delivery by biotinylated nanofibers could promote the proliferation of the mouse chondrogenic ATDC5 cells when compared with cells embedded within nanofibers with untethered IGF-1.